Hypothesis: Kisspeptin Mediates Male Hypogonadism in Obesity and Type 2 Diabetes

Citation for published version:
https://doi.org/10.1159/000299767

Digital Object Identifier (DOI):
10.1159/000299767

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Neuroendocrinology

Publisher Rights Statement:
Available under Open Access

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Hypothesis: Kisspeptin Mediates Male Hypogonadism in Obesity and Type 2 Diabetes

Jyothis T. Georgea Robert P. Millarab, c Richard A. Andersona, b

a Medical Research Council, Human Reproductive Sciences Unit, and b Division of Reproduction and Developmental Sciences, University of Edinburgh, Centre for Reproductive Biology, The Queen’s Medical Research Institute, Edinburgh, UK; c Receptor Biology Group, Division of Medical Biochemistry, University of Cape Town, Cape Town, South Africa

Abstract

Hypogonadism occurs commonly in men with type 2 diabetes (T2DM) and severe obesity. Current evidence points to a decreased secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus and thereby decreased secretion of gonadotropins from the pituitary gland as a central feature of the pathophysiology in these men. Hyperglycaemia, inflammation, leptin and oestrogen-related feedback have been proposed to make aetiological contributions to the hypogonadotropic hypogonadism of T2DM. However, the neuroendocrine signals that link these factors with modulation of GnRH neurons have yet to be identified. Kisspeptins play a central role in the modulation of GnRH secretion and, thus, downstream regulation of gonadotropins and testosterone secretion in men. Inactivating mutations of the kisspeptin receptor have been shown to cause hypogonadotropic hypogonadism in man, whilst an activating mutation is associated with precocious puberty. Data from studies in experimental animals link kisspeptin expression with individual factors known to regulate GnRH secretion, including hyperglycaemia, inflammation, leptin and oestrogen. We therefore hypothesise that decreased endogenous kisspeptin secretion is the common central pathway that links metabolic and endocrine factors in the pathology of testosterone deficiency seen in men with obesity and T2DM. We propose that the kisspeptin system plays a central role in integrating a range of metabolic inputs, thus constituting the link between energy status with the hypothalamic-pituitary-gonadal axis, and put forward potential clinical studies to test the hypothesis.

Introduction

Over the past few decades, obesity has become a global health challenge. Between 1980 and 2004 the prevalence of obesity increased from 15 to 33% in the United States – a pattern mirrored across the world [1]. Interlinked with this, the number of people with type 2 diabetes (T2DM) has also risen, and is predicted to rise further [2]. There is also an emerging consensus that T2DM and obesity are part of the same disease spectrum such that the term ‘metabolic syndrome’ is used to describe these overlapping pathophysiological processes [3].

Whilst the cardiovascular effects of T2DM and obesity have been extensively studied, the impact on fertility and hypogonadism remains relatively under-explored.
Low testosterone concentrations in men have been shown to be associated with obesity and T2DM [4]. Plasma-free testosterone, total testosterone and sex hormone-binding globulin are low in obesity and recover in proportion to the degree of weight loss [5]. In men with established T2DM, decreased plasma-free testosterone is found in a third to half of all patients [6].

The relationship between hypogonadism and metabolic status, consistently seen across race and ethnic groups [7], also seems to be bidirectional. In obese men, biochemical hypogonadism (low testosterone) increases the risk of future development of diabetes [8]. In hypogonadal individuals with T2DM, treatment with testosterone improves the glucose and lipid profile [9], and enhances quality of life and cardiac performance [10].

The pathophysiology of low plasma testosterone in men with T2DM as well as the broader neuroendocrine signalling processes by which the metabolic milieu influences reproduction remains poorly understood [11]. However, the recent discovery of kisspeptin and its cognate receptor GPR-54 (KISS1R) as modulators of GnRH and, thus, downstream secretion of gonadotropins and testosterone [12] may help solve at least a part of this complex jigsaw.

Here we review human and animal experimental data on the potential role for kisspeptin in mediating metabolic inputs that modulate the hypothalamic-pituitary-gonadal (HPG) axis and put forward propositions for clinical studies to test this central role for kisspeptin as an integrator of metabolic cues with reproductive function in men with metabolic syndrome.

Hypothesis

We hypothesise that decreased endogenous kisspeptin secretion plays a central role in mediating hypogonadotropic hypogonadism in men with obesity and T2DM.

Hypogonadism in Obesity and Diabetes

A number of possible pathologies have been proposed as causative factors for hypogonadism in individuals with obesity and/or T2DM. Metabolic factors (hyperglycaemia, inflammation, oxidative stress) and testicular factors (decreased Leydig cell function) have all been proposed as factors contributing to the hypogonadal state in these individuals [4]. However, current evidence points to a decreased secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus as the key factor [4], as evidenced by the low or relatively low luteinising hormone (LH) and follicle-stimulating hormone (FSH) concentrations in the large majority of these men with low plasma testosterone. LH pulse amplitude and secretory masses are significantly lower in obese men than in lean controls [13]. Moreover, there is a highly significant negative correlation between plasma-free testosterone and body mass [13]. A normal LH and FSH response to GnRH has also been demonstrated in obese individuals, suggesting a hypothalamic rather than a pituitary defect [14].

The Role of Kisspeptin in GnRH Secretion

Kisspeptins are peptide products of the KISS1 gene [15]. Various forms of kisspeptin have been identified, all of which have the same decapetide amino acid sequence at the C-terminus [12]. Kisspeptins regulate the reproductive axis by stimulation of their cognate receptor KISS1R (also called GPR-54) on GnRH neurons, thereby regulating LH and FSH secretion [12]. Administration of kisspeptin has been shown to increase plasma LH, FSH and testosterone in a dose-dependent manner in a number of species including man [16], and a central role of kisspeptin in the metabolic regulation of reproductive function is well-recognised [17]. Patients with mutations of KISS1R exhibit hypogonadotropic hypogonadism but normal responses to GnRH and no reported metabolic derangement [18–20]. It is also important to note that metabolic abnormalities have not been reported in knock-out models lacking kisspeptin or its receptor [21], suggesting that perturbation in the kisspeptin system is more likely to be the effect rather than the cause of a metabolic phenotype.

In rodents, two distinct populations of kisspeptin neurons exist in the arcuate (ARC) and anterior periventricular (AVPV) nuclei, with differential functional responses [22]. Kisspeptin neurons in the ARC have been shown to respond to negative feedback by gonadal steroids, while AVPV kisspeptin neurons in the female rodent respond to positive feedback by oestrogen [22]. However, AVPV is not an anatomical area present in the human hypothalamus and no kisspeptin neurons have been demonstrated in the corresponding rostral periventricular region of the third ventricle in humans [22]. The infundibular nucleus is the human homologue of the ARC where the presence of kisspeptin neurons has been documented [23]. In the rodent data reviewed here, we will focus on the kisspeptin population in the ARC nucleus as the oestrogen-mediated positive feedback seen in the female is not of particular relevance in the context of male hypogonadism. However, it has to be borne in mind that in mRNA analyses of

Kisspeptin Mediates Male Hypogonadism

Neuroendocrinology 2010;91:302–307
gene expression, whole hypothalami are often used rather than specific nuclei, such as the ARC or AVPV, thus potentially lowering the sensitivity and specificity of any changes detected in Kiss1 mRNA expression.

Support for the Hypothesis

Oestrogen-Mediated Negative Feedback and Kisspeptin

Peripheral conversion of androgens to oestrogens in obese men leads to increased circulating oestrogens, which in turn suppress the hypothalamic-pituitary axis and thus the production of testosterone [24]. Serum oestrone and 17-β-oestradiol are elevated twofold in morbidly obese men, with the urinary excretion rates of these hormones elevated in proportion to the degree of obesity [24]. Treatment with an aromatase inhibitor (preventing conversion of testosterone to oestradiol) produces a sustained normalisation of serum total testosterone in obese men with hypogonadism [25].

However, adult GnRH neurons lack oestrogen receptor-α (ER-α) and rely on signaling from other oestrogen responsive hypothalamic neurons to facilitate oestrogen-mediated regulation [26]. The phenotypic identity of cells that receive input from gonadal steroids and relay this information to GnRH neurons remains unknown; however, kisspeptin neurons appear likely to play this role [27]. The hypothalamic content of Kiss1 (mRNA) increases significantly after gonadectomy and decreases with sex steroid replacement [28]. Kisspeptin neurons in sheep express ER-α receptors [29] and in mouse models that lack functional ER-α receptors, Kiss1 mRNA expression does not change in response to oestradiol treatment [30]. A minority of kisspeptin neurons express the oestrogen receptor isoform ER-β in addition to ER-α [30]. In the absence of ER-β (in knockout mouse models), the inhibitory effect of E2 on transcription of Kiss1 is enhanced [30], indicating functional roles of both ER types in the regulation of kisspeptin neurons.

Leptin and Kisspeptin

Leptin secreted from adipocytes conveys information about the body’s energy stores to the brain and thus regulates a number of physiological processes, including inflammation, immune function and reproduction [31]. Humans and mice lacking leptin (ob/ob mice) or leptin receptor (db/db mice) develop obesity, insulin-resistant diabetes and hypogonadism [31]. In obese men, circulating androgen is inversely correlated with circulating leptin [32] and a functional resistance to leptin in human obesity has been described [33].

GnRH neurons, however, show little or no expression of Ob-R mRNA [34] and, therefore, must rely on intermediary neurons for transmission of information on leptin concentrations [34]. Kisspeptin neurons may fulfill this role, as they express leptin receptors [35]. Reversal of fasting-induced inhibition of gonadotropins by exogenous kisspeptin [36] and the ability of intracerebroventricular kisspeptin administration to correct the decrease in LH secretion seen in pubertal animals after central immunoneutralisation of endogenous leptin with antileptin antibody [37] provide further evidence for a role of kisspeptin in affecting the influence of leptin on the HPG axis.

Hypothalamic Kiss1 mRNA expression is significantly reduced in ob/ob compared to wild-type mice and are increased in ob/ob mice treated with leptin [35, 38]. Moreover, administration of leptin increases hypothalamic Kiss1 mRNA as well as LH and testosterone concentrations in hypogonadotropic diabetic male rats [38].

Hyperglycaemia and Kisspeptin

Plasma testosterone is inversely related to glycaemic control in men with T2DM. However, when compared with age- and BMI-matched men [4] as well as men with type 1 diabetes of a comparable age, men with T2DM have a higher prevalence of hypogonadism [39]. This suggests insulin resistance as well as hyperglycaemia could also play a role in the pathogenesis of hypogonadism in this setting [4]. Mice with neuron-specific deletion of insulin receptors (NIRKO mice) have increased body mass and hypogonadotropic hypogonadism, confirming that insulin sensing in the brain is required for normal activity of the HPG axis [40].

Hypothalamic Kiss1 mRNA is decreased in streptozotocin-induced diabetic rats (a model of type 1 diabetes), and the post-orchiectomy rise in Kiss1 mRNA in these hyperglycaemic animals is severely blunted [38]. Kisspeptin administration has been shown to evoke robust LH and testosterone secretion and enhance post-orchiectomy LH concentrations in hypogonadotropic streptozotocin-induced diabetic male rats [38]. Repeated administration of kisspeptin to diabetic rats also partially rescued prostate and testis weights [41]. However, no studies have yet been carried out on Kiss1 mRNA expression in animal models of T2DM.

Inflammation and Kisspeptin

Obesity and T2DM are now well recognised to be associated with inflammation and increased oxidative
stress [42]. Circulating C-reactive protein, an inflammatory marker associated with cardiovascular risk, has been shown to be significantly higher in hypogonadal men with T2DM in comparison to men with normal plasma testosterone [4].

There are emerging data linking kisspeptin and inflammation. Administration of a pro-inflammatory agent (lipopolysaccharide) decreased hypothalamic Kiss1 mRNA expression as well as plasma LH in ovariec-tomised rats [43]. Indomethacin, an anti-inflammatory drug, completely blocked both these suppressive effects [43]. Whilst inflammation has long been recognised to suppress the reproductive axis (e.g. in severe or chronic illness), these early findings suggest a link between kisspeptin and inflammation.

Figure 1 summarises the normal physiology and the proposed pathophysiology underpinning our hypothesis.

**Testing the Hypothesis**

To test the hypothesis directly, comparison between endogenous kisspeptin secretion in obese and lean subjects would have to be made. However, the concentration of kisspeptin entering the peripheral circulation from the hypothalamus is likely to be undetectable. Accessing portal circulation via petrosal sinus sampling for sampling is technically and ethically challenging. Highly specific and sensitive assay methods to measure kisspeptins are not yet widely available [44, 45]. Moreover, even if the technical barriers are overcome, circulatory concentrations of kisspeptin may not correlate with the intracranial milieu.

Recent advances in kisspeptin biology offer indirect alternatives to test our hypothesis. Kisspeptin neuronal hypertrophy and increased kisspeptin gene expression has been demonstrated in the hypothalamic infundibular nu-

---

**Fig. 1.** Normal physiology and the pathophysiological processes underpinning our hypothesis.
cles in postmenopausal women [23]. Similar post-mor-
tem histological analysis of hypothalami from obese men
may show hypotrophy of kisspeptin neurons and/or de-
creased KISS1 expression. A comparable situation of hy-
pogonadotropic hypogonadism is seen in women with hy-
pothalamic amenorrhoea who show a significantly higher
LH response to acute administration of kisspeptin-54 in
comparison to healthy women in the follicular phase of
menstrual cycle [46]. As hypogonadal men with metabol-
ic syndrome have a similar gonadotropin profile to wom-
en with hypothalamic amenorrhoea, stimulatory re-
sponses in LH to exogenous kisspeptin in these men may
also be increased, which if confirmed in exploratory stud-
ies, raises the possibility of using a provocative kisspeptin
stimulation test as a marker of metabolic status. In recent
animal studies, kisspeptin antagonists have been shown
to inhibit kisspeptin-induced LH release and also block
animal studies, kisspeptin antagonists have been shown
to inhibit kisspeptin-induced LH release and also block
the post-gonadectomy rise in LH [47]. Moreover, in male
rats with streptozocin-induced diabetes, the LH response
to kisspeptin was significantly higher than control ani-
mals [48]. By analogy, increased sensitivity to kisspeptin
agonists will potentially not have this adverse effect.

Implications of the Hypothesis

There are physiological and clinical implications if our
postulates are correct.

The pathophysiology of hypogonadism in obese men
remains poorly understood. Current evidence linking in-
sulin, leptin, oestrogen and inflammation with hypogo-
nadism fails to explain how these factors have effects on
GnRH neurons which lack corresponding receptors. If
our hypothesis is correct, kisspeptin will constitute the
neuroendocrine link conveying information about whole
body energy balance to the GnRH neuronal system.

From a translational perspective, there is potential for
pharmacological therapies to be developed to address hy-
pogonadism. A number of kisspeptin analogues are be-
ing developed with agonistic and antagonistic activities.
If our hypothesis is correct, kisspeptin agonists constitu-
tute putative therapeutic targets for low circulating tes-
tosterone seen in obesity and diabetes. Current treatment
of hypogonadism with testosterone tends to decrease
sperm production through negative feedback on FSH se-
cretion with resultant sub-fertility in at least some pa-
tients. Pharmacological modulation with kisspeptin ago-
nists will potentially not have this adverse effect.

In summary, we postulate low kisspeptin secretion
is part of the pathophysiology of hypogonadotropic hy-
pogonadism seen in men with obesity and T2DM. The
kisspeptin/KISS1R system is likely to be a central link be-
tween energy status and the HPG axis in man as has been
demonstrated in experimental animals.

Acknowledgements

J.T.G.’s current position as a Career Development Fellow is
funded by the Medical Research Council. J.T.G., R.A.A. and
R.P.M. have also been awarded a project grant from Novo Nordisk
UK Research Foundation for studies on pancreatic responses to
kisspeptin. J.T.G. has also been awarded the Sanofi-Aventis ‘Ex-
cellence in Diabetes Research Award’ for studies on hypogonad-
ism in diabetes.

References

1 Ogden CL, Yanovski SZ, Carroll MD, Flegal
K M: The epidemiology of obesity. Gastroen-

2 Wild S, Roglic G, Green A, Sicree R, King H:
Global prevalence of diabetes: estimates for
the year 2000 and projections for 2030. Dia-
betes Care 2004;27:1047–1053.

3 Alberti KG, Zimmet P, Shaw J, IDF Epidemi-
ology Task Force Consensus Group: The
metabolic syndrome – a new worldwide def-

4 Dandona P, Dhindsa S, Chaudhuri A, Bhatia
V, Topiwala S, Mohanty P: Hypogonadotro-
phic hypogonadism in type 2 diabetes, obe-
sity and the metabolic syndrome. Curr Mol

of massive weight loss on hypothalamic-pi-
tuitary-gonadal function in obese men. J

6 Dhindsa S, Prabhakar S, Sethi M, Bandyo-
padhay A, Chaudhuri A, Dandona P: Fre-
cquent occurrence of hypogonadotropic hy-
pogonadism in type 2 diabetes. J Clin
Endocrinol Metab 2004;89:5462–5468.

7 Kupelian V, Hayes FJ, Link CL, Rosen R,
McKinlay JB: Inverse association of testos-
terone and the metabolic syndrome in men
is consistent across race and ethnic groups. J
Clin Endocrinol Metab 2008;93:3403–3410.

8 Kupelian V, Page ST, Araujo AB, Travison
TG, Bremner WJ, McKinlay JB: Low sex hor-
mone-binding globulin, total testosterone,
and symptomatic androgen deficiency are
associated with development of the metabolic
syndrome in nonobese men. J Clin Endo-
crinol Metab 2006;91:843–850.

9 Kapoor D, Goodwin E, Channer KS, Jones
TH: Testosterone replacement therapy im-
proves insulin resistance, glycaemic con-
trol, visceral adiposity and hypercholester-
olaemia in hypogonadal men with type 2
906.
Kisspeptin Mediates Male Hypogonadism

Kisspeptin Mediates Male Hypogonadism

Neuroendocrinology 2010;91:302–307

307


